

Data Sharing Statement

The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2105911.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Partial data sets
Additional information about data	The mpRCT is a federation of individually regulated platforms. We will post as complete a dataset of the trial as possible
How or where can the data be obtained?	At rzarychanski@cancercare.mb.ca
When will data availability begin?	One year after publication of the trial
When will data availability end?	Five years after publication of the trial
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	At rzarychanski@cancercare.mb.ca
When will supporting documents availability begin?	One year after publication of the trial
When will supporting documents availability end?	Five years after publication of the trial
To whom will data be available?	Data will be available to researchers on request subject to sponsor restrictions
For what type of analysis or purpose?	Research
By what mechanism?	After approval of a proposal, with investigator support
Any other restrictions?	—
Additional information	—

This statement was posted on August 4, 2021, at NEJM.org.